An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: Parallel detection with fluorescence and mass spectrometry

Biomedical Chromatography

Volumn 16, Issue 3, 2002, Pages 209-218

  Sai, Kimie ^a   Kaniwa, Naoko ^a   Ozawa, Shogo ^a   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; DRUG PRODUCTS; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ACTIVE METABOLITES; ANALYTICAL METHOD; CYTOCHROMES P450; DETECTION SYSTEM; FLUORESCENCE DETECTOR; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYCAMPTOTHECIN; IRINOTECAN; PARALLEL DETECTION; SIMPLE++;

METABOLITES;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BIOMATERIAL; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CODEINE; CYTOCHROME P450 3A; DEXAMETHASONE; DICLOFENAC; DOCETAXEL; DOMPERIDONE; DRUG METABOLITE; ETOPOSIDE; FLUOROURACIL; GRANISETRON; IRINOTECAN; LOXOPROFEN; MEFENAMIC ACID; METHANOL; METOCLOPRAMIDE; MORPHINE; NAPROXEN; NAVELBINE; PACLITAXEL; PERCHLORIC ACID; PRODRUG; UNCLASSIFIED DRUG; URACIL;

ANALYTIC METHOD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG ISOLATION; DRUG MONITORING; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REVIEW; SPECTROFLUOROMETRY;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0036238608     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.137     Document Type: Review

References (25)

1. Fentomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography
2. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
3. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: Application to clinical pharmacokinetic studies
4. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
5. Modification of the hydroxyl lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
6. Identification of mammalian DNA topoisomerase I as an intercellular target of the anticancer drug camptothecin
7. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
8. Accuracy (Trueness and Precision) of Measurement Methods and Results
9. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform IAI in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
10. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
11. Proficient metabolism of irinotecan by a human intestinal carboxylesterase
12. Irinotecan (CPT-11) metabolites in human bile and urine
13. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography
14. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
15. Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry
16. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
17. Trance analysis of SN-38 in human plasma by high-performance liquid chromatography
18. CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile
19. A new metabolite of irinotecan whose formation is mediated by human hepatic cytochrome P-450 3A4
20. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan
21. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
22. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Conference report
23. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
24. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients
25. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces